The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: A 5-year prospective analysis

Clinics

Volumn 68, Issue 9, 2013, Pages 1189-1196

  Machado, Natalia P ^a   dos Reis Neto, Edgard Torres ^a   Soares, Maria Roberta M P ^a   Freitas, Daniele S ^a   Porro, Adriana ^a   Ciconelli, Rozana M ^a   Pinheiro, Marcelo M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adverse events; Ankylosing spondylitis; Rheumatoid arthritis; Skin; TNF alpha blockers

Indexed keywords

ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG EFFECT; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; NONPARAMETRIC TEST; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; QUESTIONNAIRE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SKIN; SKIN DISEASE; TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; ARTHRITIS, PSORIATIC; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SKIN; SKIN DISEASES; SPONDYLITIS, ANKYLOSING; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885236211     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(09)03     Document Type: Article

References (47)

1. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964-75, http://dx.doi.org/10.1136/ard.2009.126532.
2. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905-11, http://dx.doi.org/10.1136/ard.2011.151563.
3. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387-94, http://dx.doi.org/10.1136/ard. 2008.094946.
4. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care Res (Hoboken). 2011;63(4):465-82, http://dx.doi.org/10.1002/acr.20460.
5. American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137-74, http://dx.doi.org/10.1016/j.jaad.2010.11.055.
6. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571-607, http://dx.doi.org/10.1136/gut.2010.224154.
7. Flendrie M, Vissers WHPM, Creemers MCW, Jong EMGJ, van de Kerkhof PCM, van Riel PLCM. Dermatological conditions during TNF-a-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):666-76, http://dx.doi.org/10.1186/ar1724.
8. Baumgart DC, Grittner U, Steingraber A, Azzaro M, Philipp S. Frequency, Phenotype, Outcome, and Therapeutic Impact of Skin Reactions Following Initiation of Adalimumab Therapy: Experience from a Consecutive Cohort of Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2011;17(12):2512-20, http://dx.doi.org/10.1002/ibd. 21643.
9. Freitas DS, Machado NP, Andrigueti FV, Reis Neto ET, Pinheiro MM. Lepromatous leprosy associated with the use of anti-TNF a therapy: case report. Bras J Rheumatol. 2010;50(3):333-9.
10. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alfa neutralizing agent. N Engl J Med. 2001; 345(15):1098-104.
11. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737-44, http://dx.doi.org/10.1001/jama.2009.146.
12. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48(10):1364-71, http://dx.doi.org/10.1086/598331.
13. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alfa therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68(2):209-15, http://dx.doi.org/10.1136/ard.2007.087288.
14. Fiorino G, Allez M, Alberto M, Danese S. Anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29(9):921-7, http://dx.doi.org/10.1111/j.1365-2036.2009.03955.x.
15. Amari W, Zeringue AL, McDonald JR, Caplan L, Eisen SA, Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology. 2011;50(8):1431-9, http://dx.doi.org/10.1093/rheumatology/ker113.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24, http://dx.doi.org/10.1002/art.1780310302.
17. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-8, http://dx.doi.org/10.1002/art.1780270401.
18. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665-73, http://dx.doi.org/10.1002/art.21972.
19. Bértolo MB, Brenol CV, Schainberg CG, Neubarth F, de Lima FAC, Laurindo IM, et al. Atualização do consenso brasileiro no diagnóstico e tratamento da artrite reumatóide. Rev Bras Reumatol. 2007;47(3):151-9.
20. Sampaio-Barros PD, Azevedo VF, Bonfiglioli R, Campos WR, Carneiro SCS, Carvalho MAP, et al. Consenso Brasileiro de Espondiloartropatias: Espondilite Anquilosante e Artrite Psoriásica Diagnóstico e Tratamento - Primeira Revisão. Rev Bras Reumatol. 2007;47(3):233-49, http://dx.doi.org/10.1590/S0482-50042007000400001.
21. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8, http://dx.doi.org/10.1002/art.1780380107.
22. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.
23. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44, http://dx.doi.org/10.1159/000250839.
24. Gell PGH. & Coombs, RRA. (Eds) (1963) Clinical Aspects of immunology. Blackwell, Oxford.
25. Winthrop LK. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2(11):602-10, http://dx.doi.org/10.1038/ncprheum0336.
26. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616-23, http://dx.doi.org/10.1136/ard.2010.137422.
27. Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, et al. TNF-a Antagonist Use and Risk of Hospitalization for Infection in a National Cohort of Veterans With Rheumatoid Arthritis. Medicine (Baltimore). 2011;90(2):139-45.
28. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther. 2011;13(4):R139, http://dx.doi.org/10.1186/ar3453.
29. Benucci M, Manfredi M, Saviola G, Baiardi P, Campi P. Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(2):333-6.
30. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59(7):996-1001, http://dx.doi.org/10.1002/art.23835.
31. Carter JD, Gerard HC, Hudson AP. Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. Ann Rheum Dis. 2008;67(8):1181-3, http://dx.doi.org/10.1136/ard.2007.082842.
32. Ritchlin C, Tausk F. A medical conundrum: onset of psoriasis in patients receiving anti-tumor necrosis factor agents. Ann Rheum Dis. 2006;65(12):1541-4, http://dx.doi.org/10.1136/ard.2006.059261.
33. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alfa therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68(2):209-15, http://dx.doi.org/10.1136/ard.2007.087288.
34. Pontikaki I, Shahi E, Frasin LA, Gianotti R, Gelmetti C, Gerloni V, et al. Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2012;42(2):131-4, http://dx.doi.org/10.1007/s12016-011-8262-2.
35. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64 Suppl 2:ii30-6, http://dx.doi.org/10.1136/ard.2004.031120.
36. Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-inhibitors. Rheumatology (Oxford). 2005;44(2):172-5, http://dx.doi.org/10.1093/rheumatology/keh437.
37. Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha? J Clin Rheumatol. 2008;14(6):353-6, http://dx.doi.org/10.1097/RHU.0b013e318190dd88.
38. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor a antagonists. Ann Rheum Dis. 2006;65(3):405-7, http://dx.doi.org/10.1136/ard.2005.037424.
39. Tomi NS, Kranke B, Aberer E. Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects. J Am Acad Dermatol. 2005;53(1):67-72, http://dx.doi.org/10.1016/j.jaad.2005.02.034.
40. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6(6):R535-43, http://dx.doi.org/10.1186/ar1440.
41. Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFa. Ann Rheum Dis. 2005;64(3):403-7.
42. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor a agents. Semin Arthritis Rheum. 2008;37(6):381-7, http://dx.doi.org/10.1016/j.semarthrit.2007.08.003.
43. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359(9306):579-80, http://dx.doi.org/10.1016/S0140-6736(02)07714-0.
44. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994;20(1):61-86.
45. Sarzi-Puttini, Atzeni F, Captano E, Soni F, Luibtano E, Doria A. Drug-induced lupus erythematosus. Autoimmunity. 2005;38(7):507-18, http://dx.doi.org/10.1080/08916930500285857.
46. Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15(11):757-61, http://dx.doi.org/10.1177/0961203306070000.
47. Wallis RS, Broder MS, Wong JY, Hanson ME. Beenhouwer DO. Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists. Clin Infect Dis. 2004;38(9):1261-5, http://dx.doi.org/10.1086/383317.